WAM
RYTM icon

Wolverine Asset Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Wolverine Asset Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-15,000
Closed -$435K – 1648
2017
Q4 		$435K Buy
+15,000
New +$397K ﹤0.01% 936

Other funds holding RYTM

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
TG
TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Wolverine Asset Management's RYTM Position: Q1 2018 in Review

Wolverine Asset Management sold out of Rhythm Pharmaceuticals (RYTM) in Q1 2018, closing a stake of 15,000 shares — an estimated $435K sold.

Wolverine Asset Management first reported a position in RYTM in Q4 2017 and held it in 1 quarter. The position peaked at $435K in Q4 2017. 55 funds tracked by Wall St. Rank hold RYTM as of Q1 2018.

  • Wolverine Asset Management reported no remaining Rhythm Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Wolverine Asset Management sold 15,000 Rhythm Pharmaceuticals shares in Q1 2018, an estimated $435K.
  • Wolverine Asset Management first reported a position in Rhythm Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Wolverine Asset Management's Rhythm Pharmaceuticals position peaked at $435K in Q4 2017.
  • 55 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2018.

Based on Wolverine Asset Management's 13F filing for Q1 2018, filed 15 May 2018.